Notable 52-Week Highs and Lows 9/9: (LXRX) (FNSR) (SWFT) High; (VMEM) (NCLH) (NVO) Low

September 9, 2016 3:27 PM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

52-Week High:
  • Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) $21.74. Lexicon Pharma announced that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin.

  • Finisar (Nasdaq: FNSR) $27.50. Finisar reported Q1 EPS of $0.38, which was $0.08 better than the analyst estimate of $0.30. Revenue for the quarter came in at $341.3 million versus the consensus estimate of $332.75 million. Finisar sees Q2 2017 EPS of $0.44-$0.50, versus the consensus of $0.32. Finisar sees Q2 2017 revenue of $355-375 million, versus the consensus of $342.9 million.

  • Swift Transportation (NYSE: SWFT) $21.07. Swift Transportation announced the retirement of Founder and CEO Jerry Moyes, effective as of December 31, 2016. Richard Stocking, who joined Swift in 1992 and has served as Swift’s President and Chief Operating Officer since 2010, has been unanimously appointed by the Board of Directors as President and Chief Executive Officer. During the transition period, until December 31, 2016, Mr. Moyes and Mr. Stocking will serve as Co-CEOs, although all day-to-day responsibilities will be immediately transitioned to Mr. Stocking. Commencing January 1, 2017, Mr. Moyes will serve as Founder and Chairman Emeritus and a member of the Board of Directors.
52-Week Low:
  • Violin Memory (NYSE: VMEM) $0.94. Violin Memory reported Q2 EPS of ($0.59), versus the analyst estimate of ($0.56). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $11 million

  • Norwegian Cruise Line Holdings (Nasdaq: NCLH) $34.16. Norwegian Cruise Line Holdings shares breaking a recent slide as Bernstein started coverage on the stock with an Outperform rating and $44 price target.

  • Novo Nordisk (NYSE: NVO) $44.25. JPMorgan downgraded Novo Nordisk from Overweight to Neutral.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

JPMorgan, Sanford C. Bernstein

Add Your Comment